Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma

Hydroxyurea (HU) is an anti-neoplastic drug used in the treatment of chronic myeloproliferative neoplasms (MPNs). HU is associated with cutaneous adverse effects, whereas severe complications such as leg ulcers and non-melanoma skin cancers (NMSCs) are rare and only observed after long-term treatment. We herein report a patient with essential thrombocythemia (ET) treated chronically with HU, and who developed refractory bilateral leg ulcers complicated by squamous cell carcinoma (SCC) over both heels. The patient was successfully managed by multiple debridement stages and skin grafting surgeries.

HU is generally used to treat myeloproliferative disorders, particularly essential thrombocythemia (ET) and polycythemia vera (PV). Common cutaneous side effects include xerosis, hyperpigmentation of the skin folds and nails, alopecia, scaling, skin atrophy, lichen-planus and dermatomyositis-like eruptions. In addition, rare and more severe cutaneous manifestations, such as non-healing leg ulcers and cutaneous malignancies have been reported in a few studies and case reports. Chronic non-healing ulcers are at increased risk of harboring squamous cell carcinoma (SCC). Several cases of HU-related cutaneous SCCs have been reported. The synergistic action of long-term HU and ultraviolet (UV) light exposures are strongly implicated in the development of cutaneous SCC. This report demonstrates a successful multidisciplinary management of HU-induced bilateral chronic leg ulcers associated with SCC.

CASE PRESENTATION

A 60-year-old Caucasian woman presented to our clinic for evaluation of thrombocytosis (900 × 10^9/L) that was incidentally discovered after suffering a myocardial infarction. Bone marrow evaluation revealed hypercellularity with increased megakaryocytes. The patient had diploid karyotype, and molecular analysis revealed JAK2 V617F mutation with no BCR–ABL fusion gene. The diagnosis of ET was made based on the World Health Organization (WHO) 2008 criteria. She was started on low dose aspirin and HU.

In the fifth year of HU treatment, she developed painful erythematous, ulcerated plaques over the plantar aspect of bilateral feet (Fig. 1). HU was discontinued and she was switched to anagrelide. However, she was unable to tolerate it and was shifted to peginterferon α-2a (Pegasys®) with subsequent improvement. Nevertheless, the leg ulcers did not heal completely after HU discontinuation. Three years later, the patient developed painful fleshy erythematous papules within the heel ulcers. A punch biopsy revealed an infiltrating and keratinizing SCC with focal areas of SCC in-situ (Bowen’s disease). Bilateral surgical excision revealed...
the same pathologic changes (Fig. 2). After one surgical debridement and two grafting procedures, the patient had complete resolution of the lesions, and no recurrence with three years of follow-up (Fig. 3).

**DISCUSSION**

HU is the approved first-line therapy for patients with high risk ET and PV. Only ten case reports in the literature illustrate an association between long-term HU therapy and SCC in Ph-negative MPNs patients (Table 1). Among them, only one case described a chronic leg ulcer with malignant degeneration into SCC.

Discontinuation of HU is the cornerstone of treatment of HU-related ulcers. Dermatologic examination should be emphasized during long-term HU therapy. This report highlights the importance of repeated skin ulcer biopsies in patients on HU, especially if the ulcers persist despite HU discontinuation. This early intervention is crucial for the early diagnosis of skin cancer and for prompt management. Furthermore, any diagnosed skin cancer should be addressed by a multidisciplinary team approach.
<table>
<thead>
<tr>
<th>Authors</th>
<th>No. of cases</th>
<th>Disease</th>
<th>Age/sex</th>
<th>HU dose</th>
<th>HU duration</th>
<th>Description of skin SCC</th>
<th>Other HU related toxicity</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saraceno et al.</td>
<td>7</td>
<td>PMF</td>
<td>81/M</td>
<td>1 g/d</td>
<td>6 months</td>
<td>Multiple face and extremities skin SCC</td>
<td>– Actinic keratoses</td>
<td>Imiquimod cream 5%</td>
<td>CR of skin SCC</td>
</tr>
<tr>
<td>Hoff et al.</td>
<td>1</td>
<td>PV</td>
<td>86/F</td>
<td>n/a</td>
<td>8 years</td>
<td>SCC in the lower leg</td>
<td>– Keratoacanthomas</td>
<td>HU was not stopped</td>
<td>Nail unchanged</td>
</tr>
<tr>
<td>Schleubinger et al.</td>
<td>1</td>
<td>ET</td>
<td>80/F</td>
<td>750 mg/d</td>
<td>13 years</td>
<td>Multiple SCC of the face</td>
<td>– Actinic keratoses</td>
<td>HU was stopped</td>
<td>CR of skin SCC and actinic keratoses</td>
</tr>
<tr>
<td>Zaccaria et al.</td>
<td>1</td>
<td>ET</td>
<td>73/M</td>
<td>1 g/d</td>
<td>12 years</td>
<td>Five SCC of the face</td>
<td>– Painful ulcers</td>
<td>Cryotherapy for keratoses</td>
<td></td>
</tr>
<tr>
<td>Stone et al.</td>
<td>1</td>
<td>PV</td>
<td>62/F</td>
<td>n/a</td>
<td>9 years</td>
<td>Left heel SCC on top of non healing ulcer</td>
<td>– Hyperkeratoses</td>
<td>Excision for SCC</td>
<td>CR of skin SCC and actinic keratoses</td>
</tr>
<tr>
<td>Callot-Mellot et al.</td>
<td>2</td>
<td>ET-PV</td>
<td>1–64/M</td>
<td>Cumulative doses</td>
<td>1–5.5 years</td>
<td>1–3 skin SCC 2- In situ SCC on dorsal face of a finger</td>
<td>– Dermatomyositis-like eruption together with a leg ulceration</td>
<td>HU was stopped</td>
<td>HU was stopped</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>– Poikilodermatoskeratotic lesions</td>
<td>Busulfan 8 mg/day</td>
<td>Complete healing of the wound after multidisciplinary treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>– Non healing ulcer of the left heel</td>
<td>HU was stopped</td>
<td>Multiple surgical debridement</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>– Face basal cell carcinoma</td>
<td>Busulfan was introduced</td>
<td>2: No recurrence</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HU was stopped Surgical excision</td>
<td>Surgical excision and discontinuation of HU</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Busulfan was introduced</td>
<td>Improvement after HU discontinuation</td>
</tr>
<tr>
<td>Esteve et al.</td>
<td>1</td>
<td>PV</td>
<td>83/F</td>
<td>1 g/day</td>
<td>13 years</td>
<td>7 skin SCC</td>
<td>– Oral SCC</td>
<td>HU was stopped</td>
<td>New SCC despite HU discontinuation</td>
</tr>
</tbody>
</table>

PMF, primary myelofibrosis; SCC, squamous cell carcinoma; ET, essential thrombocythemia; PV, polycythemia vera; CR, complete remission; HU, hydroxyurea.
CONFLICT OF INTEREST

None.

Ahmad Antar a, Rim S Ishak b, Zaher K Otrock c, Nadim El-Majzoub d, Samer Ghosn b, Rami Mahfouz d, Ali T Taher a,*

* Corresponding author at: Department of Internal Medicine, Division of Hematology-Oncology, Division, American University of Beirut Medical Center, P.O. Box 11-0236, Riad El-Solh, 1107 2020 Beirut, Lebanon.

ª 2014 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

REFERENCES


© 2014 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). DOI: http://dx.doi.org/10.1016/j.hemonc.2014.09.008